The total trade value of SCO Member States has increased nearly 100 times over the past 20 years

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

DYU Raises Nearly CNY 100 Million in Pre-B Round to Expand Overseas Retail and Smart-Mobility Products

DYU（大鱼智行）, a Chinese electric-bike and smart light-mobility company, announced on September 10 that it had completed a Pre-B funding round of nearly CNY 100 million. Tongxin Capital（同鑫资本）led the round, with several other institutional investors participating. The proceeds will support product development, AI capabilities, international brand building and supply-chain improvements.

Anjoy Foods Plans USD 74.25 Million Indonesia Joint Venture to Expand Local Production

Anjoy Foods Group（安井食品）has approved a joint venture to establish food production and sales operations in Indonesia, with the two partners committing combined cash contributions of at least USD 74.25 million. The board approved the proposal on September 9, according to a company announcement dated September 10.

Chinese Restaurant Brands Going Global: What Keeps Customers Coming Back After the Opening?

How long can the queues outside a brand’s first overseas store last? And how many customers drawn in by the novelty will become regulars? For Chinese restaurant brands expanding internationally, opening a store is only the beginning of the challenge of building a local business and retaining customers.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.